Confirmation of post-offer intention statements

Source: RNS
RNS Number : 0639Z
Takeda Pharmaceutical Company Ltd
08 January 2020
 

Better Health, Brighter Future

 

 

 

 

 

News Release

 

 

THE FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO THE REQUIREMENTS OF RULE 19.6(C) OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE"), WHICH, INTER ALIA, REQUIRES A PARTY TO AN OFFER TO MAKE AN ANNOUNCEMENT AT THE END OF A PERIOD OF 12 MONTHS FROM THE DATE ON WHICH THE OFFER PERIOD ENDED CONFIRMING WHETHER IT HAS TAKEN, OR NOT TAKEN, THE COURSE OF ACTION SET OUT IN ITS STATED INTENTIONS

 

FOR IMMEDIATE RELEASE

 

Rule 19.6(c) confirmation of post-offer intention statements

 

Osaka, Japan, January 8, 2020 --- Takeda Pharmaceutical Company Limited ("Takeda") announces that, further to the completion of its recommended offer for the entire issued and to be issued ordinary share capital of Shire plc ("Shire") on January 8, 2019, its board of directors has duly confirmed in writing to The Panel on Takeovers and Mergers in accordance with the requirements of Rule 19.6(c) of the Code that Takeda has complied with its post-offer statements of intent made pursuant to Rules 2.7(c)(iv) and 24.2 of the Code, as originally detailed in its announcement of 8 May 2018 and the Shire scheme document published on 12 November 2018.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
OUPGZGGMGNFGGZZ